Enanta Pharmaceuticals | ENTA - Interest Expense On Debt


Enanta Pharmaceuticals reported $1.96M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Amgen USD 657M 4M Mar/2026
Anika Therapeutics 179.39M 556.84M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Immunic 197K 222K Dec/2025
Incyte USD 569K 13K Mar/2026
Insmed USD 20.08M 517K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 479M 67M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 343M 39M Mar/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 671M 40M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025